Table 3. Comparison of the therapeutic efficacies in the combination group.
| Clinical data | NX combination group (%) |
||||
|---|---|---|---|---|---|
| n | ORR (%) | P value | CBR (%) | P value | |
| Age | 0.991 | 0.82 | |||
| ≥60 years | 18 | 11 (61.1) | 15 (83.3) | ||
| <60 years | 80 | 49 (61.2) | 62 (77.5) | ||
| Hormone receptor | 0.547 | 0.351 | |||
| Positive | 53 | 31 (58.5) | 42 (79.2) | ||
| Negative | 45 | 29 (64.4) | 32 (71.1) | ||
| Her-2 | 0.891 | 0.802 | |||
| Positive | 43 | 26 (60.5) | 33 (76.7) | ||
| Negative | 55 | 34 (61.8) | 41 (74.5) | ||
| Previous treatment | 0.289 | 0.644 | |||
| First-line | 53 | 35 (66.0) | 41 (77.4) | ||
| Second-line and above | 45 | 25 (55.6) | 33 (73.3) | ||
| Metastatic sites | 0.942 | 0.935 | |||
| Viscera | 77 | 47 (61.0) | 58 (75.3) | ||
| Non-viscera | 21 | 13 (61.9) | 16 (76.2) | ||
| DFS | 0.101 | 0.714 | |||
| >2 years | 44 | 23 (52.3) | 34 (77.3) | ||
| ≤2 years | 54 | 37 (68.5) | 40 (74.1) | ||
NX, vinorelbine combined with capecitabine; ORR, overall response rate; CBR, clinical benefit rate; DFS, disease-free survival.